---
title: Recent Advancements and Approvals in Wet AMD Treatments
description: Explore recent advancements and approvals in wet AMD treatments, highlighting the latest breakthroughs and innovative therapies for patients.
---

[Vision Executives Blog](https://visionexecutives.com/blog)

# [Recent Advancements and Approvals in Wet AMD Treatments](https://visionexecutives.com/blog/recent-advancements-and-approvals-in-wet-amd-treatments)

 Written by [Vision Executives](https://visionexecutives.com/blog/author/vision-executives) | Jul 25, 2024 4:09:22 PM

𝐆𝐞𝐧𝐞𝐧𝐭𝐞𝐜𝐡 𝐭𝐨 𝐑𝐞𝐢𝐧𝐭𝐫𝐨𝐝𝐮𝐜𝐞 𝐒𝐮𝐬𝐯𝐢𝐦𝐨 𝐎𝐜𝐮𝐥𝐚𝐫 𝐈𝐦𝐩𝐥𝐚𝐧𝐭 𝐟𝐨𝐫 𝐖𝐞𝐭 𝐀𝐌𝐃  
💉[Genentech](https://www.linkedin.com/company/genentech/) has announced the upcoming reintroduction of Susvimo (ranibizumab injection) 100 mg/mL, designed for intravitreal use via an ocular implant to treat wet age-related macular degeneration (AMD). After a voluntary recall in October 2022 due to performance standard issues discovered during reliability testing, Genentech has made significant updates to the implant and refill needle. These enhancements ensure rigorous performance standards are met, with improvements implemented in manufacturing processes to boost reliability. Retina specialists and their patients in the United States can expect the availability of Susvimo in the coming weeks.

𝐎𝐮𝐭𝐥𝐨𝐨𝐤 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐑𝐞𝐜𝐞𝐢𝐯𝐞𝐬 𝐔𝐊 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐨𝐟 𝐋𝐲𝐭𝐞𝐧𝐚𝐯𝐚 𝐟𝐨𝐫 𝐖𝐞𝐭 𝐀𝐌𝐃 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭  
👁 [Outlook Therapeutics, Inc.](https://www.linkedin.com/company/outlook-therapeutics/) has secured marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Lytenava (bevacizumab gamma), a treatment for wet age-related macular degeneration (AMD). Lytenava is now the first and only authorized ophthalmic formulation of bevacizumab for wet AMD treatment in both the EU and UK. In collaboration with [Cencora](https://www.linkedin.com/company/cencoraglobal/) (formerly AmerisourceBergen), Outlook Therapeutics plans to support the global commercial launch of Lytenava, ensuring efficient distribution and accessibility for patients.

𝐆𝐞𝐧𝐞𝐭𝐞𝐜𝐡’𝐬 𝐕𝐚𝐛𝐲𝐬𝐦𝐨 𝐏𝐅𝐒 𝐄𝐚𝐫𝐧𝐬 𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐟𝐨𝐫 𝐑𝐞𝐭𝐢𝐧𝐚𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞𝐬  
🧪 [Genentech](https://www.linkedin.com/company/genentech/), a member of the [Roche](https://www.linkedin.com/company/roche/) Group, has received FDA approval for Vabysmo Prefilled Syringe (PFS) for treating three potentially blinding retinal diseases. The Vabysmo 6.0 mg single-dose PFS delivers the same medicine as the previously available Vabysmo vials but in a more convenient, ready-to-use format. The approved indications for Vabysmo include wet AMD, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). This approval represents a significant step forward in providing effective treatments for these serious retinal conditions.

[View full post](https://visionexecutives.com/blog/recent-advancements-and-approvals-in-wet-amd-treatments)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Vision Executives"
  },
  "dateModified" : "2024-07-25T16:09:22.629Z",
  "datePublished" : "2024-07-25T16:09:22Z",
  "headline" : "Recent Advancements and Approvals in Wet AMD Treatments",
  "image" : {
    "@type" : "ImageObject",
    "height" : 1080,
    "url" : "https://139544819.fs1.hubspotusercontent-eu1.net/hubfs/139544819/AMD%20Update%20-%20Content%20Post.png",
    "width" : 1080
  },
  "mainEntityOfPage" : "https://visionexecutives.com/blog/recent-advancements-and-approvals-in-wet-amd-treatments",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60,
      "url" : "/hs/hsstatic/content_shared_assets/static-1.4092/img/default-amp-logo.png",
      "width" : 60
    },
    "name" : "Vision Executives Blog"
  }
}
```